Andrew Ratz, Ph.D., Joins Neurocrine Biosciences as Senior Vice President of Drug Development, Delivery and Device

Company Overview - Neurocrine Biosciences is a leading biopharmaceutical company focused on neuroscience, dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders [3] - The company has a diverse portfolio that includes FDA-approved treatments for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia, endometriosis, and uterine fibroids, as well as a robust pipeline with multiple compounds in mid- to late-phase clinical development [3] Leadership Change - Dr. Ratz has joined Neurocrine after a 28-year career at Eli Lilly, where he contributed to the development and successful registration of over 25 products across various therapeutic areas [1] - He served as Senior Vice President and Head of the Drug Delivery, Device and Connected Solutions organization at Lilly, leading the design and development of drug-device combination products [1][2] - Dr. Ratz expressed excitement about contributing to Neurocrine's innovative work and making a lasting impact on patients' lives through science and discovery [2]